Free Newsletter
SPOTLIGHT: Vaccine a success for human-to-human H5N1 case
A confirmed case of bird flu in China has confirmed that the threat of human-to-human contagion is still largely limited to the blood relatives of those infected. In an important case for vaccine developers, the man recovered after he was given plasma drawn from a woman who had received an experimental bird flu vaccine that had been made from whole, killed H5N1. The vaccine was made by Sinovac from a 2004 Vietnamese strain of the disease. If researchers can show that the recovery was linked to the vaccine, the whole virus vaccine could prove a key to spurring immunity to a range of possible mutations of H5N1. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: